Brain infarction
Conditions
Interventions
None listed
Sponsors
OASIS STUDY Research Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients whose last attack occurred more than 1 month ago 2. Outpatients (including hospitalization for rehabilitation) 3. Japanese nationality 4. Patients who consented to participate in this study 5. Group I: Patients with dizziness, vertigo, presyncope, and light-headedness which are likely due to secondary chronic cerebral circulation impairment associated with sequelae of brain infarction, and patients for whom KETAS (IBUDILAST) was prescribed Group II: Patients without dizziness, vertigo, presyncope, and light-headedness which are likely due to chronic cerebral circulation impairment associated with sequelae of brain infarction
Exclusion criteria
Exclusion criteria: 1. Patients who cannot read, understand and fill in the questionnaire by themselves 2. Patients who idle their time away 3. Patients who are hospitalized 4. Patients who are undergoing treatment for dizziness, vertigo, presyncope, light-headedness which are likely due to chronic cerebral circulation impairment associated with sequelae of brain infarction 5. Patients whose dizziness, vertigo, presyncope, and light-headedness is definitely or likely caused by Meniere disease, vestibular neuronitis, benign paroxysmal positional vertigo, otitis media, or epilepsy 6. Patients whom the investigator judges are not suitable to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the SF-36 v2 score and to investigate the effect on QOL of vertigo, dizziness, presyncope, and light-headedness after chronic brain infarction | — |
Countries
Japan
Contacts
Public ContactTakashi Shimokoube
Kyorin Pharmaceutical Co., Ltd P.L.C. Management Department
Outcome results
None listed